Clininal Studies Reporting Guidelines


Randomized trials (CONSORT)
 Observational studies (STROBE)
Systematic reviews (PRISMA)
Case reports (CARE)
Qualitative research (SRQR
Diagnostic / prognostic studies (STARD)
Quality improvement studies (SQUIRE)
Economic evaluations (CHEERS)  
Animal pre-clinical studies (ARRIVE)
Study protocols (SPIRIT)
Clinical practice guidelines (AGREE)


Publishing Policy

Elmer Press Publishing Policies, and Guidelines to follow, click for details......


Our journals are open access, which means all the contents of the journals are accessible freely to all viewers from every part of the world as long as they have internet accessibility, More...

English Editing Service

This Editing service is for (1) manuscripts submitted to Elmer Press journals, accepted for their scientific contents, but the language requires extensive and intensive editing; (2) those manuscripts not to be submitted to our journals. More...

Contact Us


Elmer Press Inc.
9225 Leslie Street, Suite 201
Richmond Hill
Ontario, L4B 3H6
Tel:  647-671-2629
Fax: 647-498-1289


Elmer Press publishes open access journals in clinical medicine fields, we are glad to collaborate with medical professional societies, institutions, academic organizations and bodies, to promote medical research and healthcare. Please contact: production"at" for details.

Journals in PubMed

Elmer Press publishes open access journals in various clinical medicine disciplines, currently we have the following journals fully indexed in PubMed and PubMed Central. Indexed by PubMed denotes the wide accessible and searchable of published articles to world researchers. Gastroenterology Research; Cardiology Research; Journal of Clinical Medicine Research; World Journal of Oncology.

Journals in Web of Science-ESCI

Emerging Sources Citation Index (ESCI) is a new index in the Web of Science™ Core Collection, Elmer Press has 3 journals indexed by ESCI, including Gastroenterology Research, Cardiology Research, and Journal of Endocrinology and Metabolism. For more details about ESCI, please click here.

Journals Permanent Archiving

All journals published by Elmer Press are archived in Portico, which provides permanent digital archiving for scholarly journals.

For Librarians



All journals published by Elmer Press Inc are fully open access, fulltexts of all articles can be viewed online for free immediately after publishing. For print journal subscription, please contact us. More...

Latest Articles

Cytoskeletal Tropomyosin as a Biomarker in Clostridium difficile Infection

by Elena A. Usacheva et al.
Journal of Clinical Medicine Research, 2019; Feburay, 11(2):98-105.
Current diagnostics of Clostridium difficile infection (CDI) heavily relies on detection of the disease-causing organism. The objective of this study was to investigate a cytoskeletal protein, tropomyosin (Tpm), as a CDI biomarker.

 Open Access

Sarcoidosis Uveitis Mimicking the Presentation of Intraocular Lymphoma

by Jeremy G. Light et al.
Journal of Medical Cases, 2019; 10(1):4-7.
A 73-year-old female presented with flashes and decreased vision in her left eye over a 2-week period. The patient had no previous ocular medical history. Initial fundal examination revealed vitritis (vitreous inflammation) with retinal hemorrhage and subretinal yellowish lesions in the left eye.

 Open Access

Sorafenib-Related Adverse Events in Predicting the Early Radiologic Responses of Hepatocellular Carcinoma

by Shou-Wu Lee et al
Gastroenterology Research, 2019;12(1):16-20.
Hepatocellular carcinoma (HCC) has a poor prognosis with low chemotherapeutic efficiency to medications except to sorafenib. Previous studies showed that adverse events (AEs) of sorafenib can predict therapy efficacy to HCC. The aim of the study is to evaluate the early efficacy and AEs of sorafenib therapy. The database of HCC patients receiving sorafenib at Taichung Veterans General Hospital during the period from June 2012 to October 2016 was analyzed. All HCC cases were Barcelona Clinic Liver Cancer (BCLC) classification stage C. The early efficacy of sorafenib was classified according to the mRECIST criteria as either partial response (PR), stable disease (SD) or progressive disease (PD).

 Open Access